Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $39.18M (cash outflow) rose 121.2% year over year, behind the +296.2% change in trailing-twelve-month net income. Sequentially, it fell 57.7% from the prior quarter.

Context

  • Net income amounted to 4658.6% of revenue in FY2025, up 4459.7 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$53.84M (-58.7%) for the fiscal year ending Dec 2026, a slowdown from the +68.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$39.18M-57.7% QoQ
Last fiscal yearDec 2025
-$130.3M+68.3% YoY
LTMMar 2026
-$151.77M+296.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+121.2%-267.5%-388.7 pp
1 year+68.3%-58.7%-127.0 pp
3-year CAGR—-10.6%—
5-year CAGR-21.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(130.3M) USD
Year-over-year change
-68.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +296.2% is the highest of 9, against a peer median of +3.1%.
  • Net income amounts to 8550.6% of revenue for RNAC, versus a peer median of 180.3%.
RNAC Competitors
Net Income for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$151.77M USD+296.2%—8550.6%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M USD-216.1%+23.4%143627.1%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$69.87M USD+152.1%+61.9%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$57.09M USD-16.9%+0.6%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$42.72M USD+84.6%+27.3%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$32.96M USD———
MDWDMediWound Ltd.LTM Mar 2026$26.1M USD+23.0%+6.8%180.3%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$8.38M USD-42.0%-24.3%16.4%
Peer median (excluding RNAC) —+3.1%+19.8%180.3%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Depreciation & Amortization1.25M1.29M843K1.15M2.96M
Deferred Income Tax2.4M(21.4M)(19M)287K(9.19M)
Stock-Based Compensation7.72M11.19M22.52M6.58M10.52M
Change in Working Capital(48.19M)(60.38M)4.97M(5.79M)(8.06M)
Accounts Receivables(2.69M)3.32M907K7.98M(243K)
Inventory211K920K000
Accounts Payables(219K)92K2.83M(2.93M)1.07M
Other Working Capital(45.5M)(64.71M)1.23M(10.84M)(8.89M)
Other Non-Cash Items2.13M2.29M159.21M51.52M60.14M
Operating Cash Flow(60.38M)(31.63M)(51.16M)(23.67M)(73.94M)
Capital Expenditures(1.09M)(1.2M)(206K)(9.09M)(5.45M)
Acquisitions (Net)006.56M351K0
Purchases of Investments(32.46M)(33.5M)000
Sales of Investments16.4M19.7M28.25M00
Other Investing Activities00000
Investing Cash Flow(17.14M)(15M)34.61M(8.74M)(5.45M)
Debt Repayment00(27.46M)00
Common Stock Issued51.96M38.98M0124.44M(301K)
Common Stock Repurchased00(6.17M)00
Dividends Paid00000
Other Financing Activities939K235K231K3.99M(7.75M)
Financing Cash Flow52.9M39.22M(13.15M)168.43M(8.06M)
Effect of Forex Changes(3K)20K(53K)(21K)45K
Net Change in Cash(24.63M)(7.4M)(29.75M)135.99M(87.41M)
Free Cash Flow(61.47M)(32.83M)(51.37M)(32.77M)(79.4M)

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.